Literature DB >> 1467845

Phosphoramidon blocks big-endothelin-1 but not endothelin-1 enhancement of vascular permeability in the rat.

S Lehoux1, G E Plante, M G Sirois, P Sirois, P D'Orléans-Juste.   

Abstract

1. Changes in vascular permeability following intravenous injections of human big-endothelin-1 (big-ET-1) and endothelin-1 (ET-1) were measured by extravasation of Evans blue dye (EB, 20 mg kg-1) in selected tissues. 2. A low dose of big-ET-1 (40 pmol kg-1) failed to alter vascular permeability but a dose of 400 pmol kg-1 increased EB extravasation in the trachea, upper and lower bronchi, and lung parenchyma by 55 to 69% (P < 0.05). Vascular permeability was also enhanced in the liver, spleen, kidney, heart, and diaphragm by 20, 14, 41, 25, and 67%, respectively (P < 0.05). 3. Upon injection of ET-1 (400 pmol kg-1), EB extravasation increased in the upper and lower bronchi, lung parenchyma, liver, pancreas, kidney, heart, and diaphragm. 4. Administration of ET-1 and big-ET-1 was not associated with significant systemic responses. 5. Pretreatment with phosphoramidon (PA) blocked the response to big-ET-1 in all tissues examined but this inhibitor failed to alter the response to ET-1. 6. We conclude from these results that the dose-dependent increase in vascular permeability induced by big-ET-1 in various tissues follows its conversion to ET-1 by the endothelin converting enzyme, a PA-sensitive process.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1467845      PMCID: PMC1907913          DOI: 10.1111/j.1476-5381.1992.tb13397.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  33 in total

1.  Direct visualization of effects of endothelin on the renal microvasculature.

Authors:  R Loutzenhiser; M Epstein; K Hayashi; C Horton
Journal:  Am J Physiol       Date:  1990-01

2.  Intra-arterial injections of histamine, serotonin, or bradykinin: a topographic study of vascular leakage.

Authors:  G Gabbiani; M C Badonnel; G Majno
Journal:  Proc Soc Exp Biol Med       Date:  1970-11

3.  Phosphoramidon, a metalloproteinase inhibitor, suppresses the hypertensive effect of big endothelin-1.

Authors:  Y Matsumura; K Hisaki; M Takaoka; S Morimoto
Journal:  Eur J Pharmacol       Date:  1990-08-21       Impact factor: 4.432

4.  Effect of platelet-activating factor on airway vascular permeability: possible mechanisms.

Authors:  T W Evans; K F Chung; D F Rogers; P J Barnes
Journal:  J Appl Physiol (1985)       Date:  1987-08

5.  The hemodynamic effects of endothelin-1 in the pithed rat.

Authors:  C E Walder; G R Thomas; C Thiemermann; J R Vane
Journal:  J Cardiovasc Pharmacol       Date:  1989       Impact factor: 3.105

6.  Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor.

Authors:  G de Nucci; R Thomas; P D'Orleans-Juste; E Antunes; C Walder; T D Warner; J R Vane
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

7.  Vasoactive amines and eicosanoids interactively regulate both polymorphonuclear leukocyte diapedesis and albumin permeability in vitro.

Authors:  J Doukas; H B Hechtman; D Shepro
Journal:  Microvasc Res       Date:  1989-03       Impact factor: 3.514

8.  Plasma exudation. Correlation between Evans blue dye and radiolabeled albumin in guinea pig airways in vivo.

Authors:  D F Rogers; P Boschetto; P J Barnes
Journal:  J Pharmacol Methods       Date:  1989-07

9.  Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response.

Authors:  S E Dahlén; J Björk; P Hedqvist; K E Arfors; S Hammarström; J A Lindgren; B Samuelsson
Journal:  Proc Natl Acad Sci U S A       Date:  1981-06       Impact factor: 11.205

10.  Putative precursors of endothelin have less vasoconstrictor activity in vitro but a potent pressor effect in vivo.

Authors:  T Kashiwabara; Y Inagaki; H Ohta; A Iwamatsu; M Nomizu; A Morita; K Nishikori
Journal:  FEBS Lett       Date:  1989-04-10       Impact factor: 4.124

View more
  6 in total

1.  The endothelin antagonist bosentan does not improve survival in severe experimental pancreatitis in rats.

Authors:  F Fiedler; D Ayasse; P Rohmeiss; N Gretz; C Rehbein; V Keim
Journal:  Int J Pancreatol       Date:  1999-12

Review 2.  Role of endothelin-1 in acute lung injury.

Authors:  Alejandro P Comellas; Arturo Briva
Journal:  Transl Res       Date:  2009-03-20       Impact factor: 7.012

3.  Magnesium sulfate treatment in experimental spinal cord injury: emphasis on vascular changes and early clinical results.

Authors:  Erkan Kaptanoglu; Etem Beskonakli; Ihsan Solaroglu; Asuman Kilinc; Yamac Taskin
Journal:  Neurosurg Rev       Date:  2003-05-29       Impact factor: 3.042

4.  Effects of endothelin receptor antagonists on bradykinin-induced increases in macromolecular efflux.

Authors:  W G Mayhan; I Rubinstein
Journal:  Inflammation       Date:  1994-12       Impact factor: 4.092

5.  Tezosentan reduces the microvascular filtration coefficient in isolated lungs from rats subjected to cecum ligation and puncture.

Authors:  Vladimir Kuklin; Mikhail Sovershaev; Thomas Andreasen; Vegard Skogen; Kirsti Ytrehus; Lars Bjertnaes
Journal:  Crit Care       Date:  2005-10-18       Impact factor: 9.097

Review 6.  Role of endothelin-1 in lung disease.

Authors:  K A Fagan; I F McMurtry; D M Rodman
Journal:  Respir Res       Date:  2001-02-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.